In the long human search for ways to slow the quiet erosion of Parkinson's disease, a year-long trial of 410 patients has returned a sobering answer: nicotinamide riboside, a supplement celebrated for its ability to replenish cellular energy, offered no protection and was associated with slightly worse outcomes than doing nothing. Conducted across eleven Norwegian centers and published in JAMA, the NOPARK trial reminds us that biological plausibility — however elegant — is not the same as clinical truth. The finding carries weight beyond the laboratory, since this supplement is already in mill
Year-long trial finds NAD-boosting supplement ineffective for early Parkinson's
The supplement raised NAD in blood but not in the brain where it mattered.
Mark
So the supplement actually raised NAD levels in the blood—it did what it was supposed to do chemically. Why didn't that translate to clinical benefit?
Mimi
That's the central puzzle. The blood work showed it was working. But when they measured NAD directly in the brain, there was no significant difference between the groups. The supplement may not cross the blood-brain barrier effectively, or the brain may regulate NAD differently than the bloodstream.
Luke
Wait—they only measured brain NAD in a subset of participants who underwent spectroscopy. How many is that? The narrative doesn't specify.
Mimi
The source doesn't give that number, which is a gap. But the point stands: raising peripheral NAD didn't produce the expected central nervous system effect.
Mark
And the worse outcomes in the nicotinamide riboside group—was that clearly the supplement's fault, or could it be coincidence?
Mimi
The difference was statistically significant, meaning it's unlikely to be random chance. But it was modest—2.72 points on a 236-point scale. Below what clinicians would call clinically meaningful worsening.
Luke
So it's real but small. And they don't actually know why it happened. They're offering two theories—that sustained NAD augmentation harms Parkinson's biology, or that it interferes with dopamine medications—but neither is proven.
Mimi
Exactly. The mechanism remains unexplained. That's what makes this frustrating for researchers who believed in the compound.
Mark
What about the people taking it over the counter right now? Does this trial tell them to stop?
Luke
The authors say the results don't support its use as a disease-modifying or symptomatic treatment at the dose and duration tested. But they're not saying it's dangerous. The adverse event rates were similar between groups.
Mimi
Still, for someone with early Parkinson's hoping for benefit, this trial offers no evidence it helps. That's the practical takeaway.
Mark
And the earlier trials that looked promising—what went wrong there?
Mimi
They were shorter and smaller, often exploratory. This was a rigorous phase 3 trial with 410 people over a full year. Sometimes what looks good in early work doesn't hold up at scale.
The Pulse
- A supplement widely trusted to restore cellular vitality has instead moved the needle — however modestly — in the wrong direction for people already navigating early Parkinson's disease.
- Blood NAD levels rose exactly as intended, yet the brain showed no corresponding change, exposing a critical gap between what a supplement does in the bloodstream and what it achieves where it matters most.
- Earlier short-term trials had generated genuine excitement, making this rigorous, year-long phase 3 result all the more disorienting for researchers, clinicians, and patients who had placed hope in the compound.
- Two unsettling possibilities now compete for explanation: sustained NAD elevation may disrupt biological processes in Parkinson's in ways not yet understood, or the supplement may interfere with the dopaminergic medications patients depend on daily.
- Because nicotinamide riboside is sold freely over the counter and marketed broadly as an anti-aging aid, the trial's findings land not just in academic journals but in the practical decisions of consumers who may be unknowingly affecting their own disease course.
In the long human search for ways to slow the quiet erosion of Parkinson's disease, a year-long trial of 410 patients has returned a sobering answer: nicotinamide riboside, a supplement celebrated for its ability to replenish cellular energy, offered no protection and was associated with slightly worse outcomes than doing nothing. Conducted across eleven Norwegian centers and published in JAMA, the NOPARK trial reminds us that biological plausibility — however elegant — is not the same as clinical truth. The finding carries weight beyond the laboratory, since this supplement is already in millions of medicine cabinets worldwide.
A year-long clinical trial has delivered an unwelcome verdict on nicotinamide riboside, a supplement designed to boost cellular energy by raising levels of NAD — a molecule central to mitochondrial function, DNA repair, and protein stability. Published in JAMA, the NOPARK trial enrolled 393 people with early-stage Parkinson's disease across eleven Norwegian centers and randomized them to receive either the supplement or a placebo for 52 weeks. The biological rationale had seemed compelling: NAD-related processes deteriorate in Parkinson's, animal studies showed neuroprotection, and earlier human trials had hinted at reduced brain inflammation and clinical improvement.
What the trial actually found moved in the opposite direction. Both groups improved slightly in the first thirteen weeks, likely due to medication adjustments made before enrollment. After that, trajectories diverged. By week 52, the supplement group's disease severity scores had worsened by an average of 2.45 points on a standard 236-point scale, while the placebo group improved by 0.27 points — a statistically significant difference favoring placebo. Non-motor symptoms including mood, sleep, and digestion followed the same pattern, with the supplement group reporting greater burden.
The blood work confirmed the supplement was functioning as designed: circulating NAD levels rose markedly. Yet brain spectroscopy revealed no meaningful difference in cerebral NAD between groups, suggesting the compound was raising NAD in the bloodstream without translating that into the intended neurological effect. Researchers proposed two explanations — that sustained NAD augmentation may harm biological processes in Parkinson's through unknown mechanisms, or that the supplement interacts adversely with dopaminergic medications, the standard treatment for the disease.
The implications reach well beyond the clinic. Nicotinamide riboside is sold over the counter and widely used by people hoping to optimize health and slow aging. For those with early Parkinson's disease, this trial offers no evidence of benefit and raises a cautious flag about potential modest harm. The broader investigation of NAD supplementation continues in other contexts, but for this population, at this dose and duration, the question has been answered.
A year-long clinical trial of 410 people with early Parkinson's disease has delivered an unwelcome finding: nicotinamide riboside, a supplement designed to boost cellular energy production, did not improve symptoms and was associated with slightly worse disease progression than placebo. The results, published in The Journal of the American Medical Association, contradict the promise of earlier, shorter studies that had suggested the compound might slow neurological decline.
The appeal of nicotinamide riboside rested on solid biological reasoning. The body converts this compound into NAD, a molecule involved in mitochondrial function, DNA repair, and protein stability—processes that deteriorate in Parkinson's disease. Animal studies showed neuroprotective effects. Initial human trials reported increased NAD levels in the brain, reduced inflammation in cerebrospinal fluid, and hints of clinical improvement. The NOPARK trial, conducted across 11 centers in Norway, was meant to settle whether these early signals held up under rigorous, long-term scrutiny.
The study enrolled 393 participants with early-stage Parkinson's disease, average age 65.6 years, 34 percent female. All had received a diagnosis within two years and showed confirmed dopaminergic neurodegeneration on brain imaging. Researchers randomized them to receive either 500 milligrams of nicotinamide riboside twice daily or placebo for 52 weeks. The primary measure was the Movement Disorder Society Unified Parkinson's Disease Rating Scale, a 236-point assessment where higher scores indicate greater disease severity. Clinically meaningful worsening is defined as a change of 5.2 points or more.
What the trial found was modest but consistent movement in the wrong direction. Both groups improved slightly in the first 13 weeks—likely reflecting medication adjustments made before enrollment. After that, the trajectories diverged. By week 52, the nicotinamide riboside group's disease scores had worsened by an average of 2.45 points, while the placebo group improved by 0.27 points. The difference of 2.72 points favored placebo and reached statistical significance, though it fell below the threshold for clinically meaningful worsening. Non-motor symptoms—mood changes, sleep problems, digestive difficulties—showed a similar pattern, with the supplement group reporting greater burden.
The blood work confirmed that the supplement was doing what it was supposed to do. Participants taking nicotinamide riboside showed marked increases in circulating NAD levels, with a mean between-group difference of 30 micromolar. NAD metabolic intermediates also rose significantly. Yet when researchers measured NAD levels directly in the brain using spectroscopy, they found no significant difference between groups in the ratio of cerebral NAD to ATP, the molecule that powers cellular work. The supplement was raising NAD in the bloodstream but not translating that into the intended biological effect in the brain.
The authors offered two hypotheses for why the results contradicted earlier promise. One possibility is that sustained NAD augmentation, over a full year, adversely affects biological processes in Parkinson's disease through mechanisms not yet understood. The other is that nicotinamide riboside interacts negatively with dopaminergic medications—the standard treatment for Parkinson's. Preclinical evidence suggests the compound may affect dopamine metabolism. Dopamine transporter binding declined in both groups, but the difference was not statistically significant, leaving this question unresolved.
The trial had limitations worth noting. Patients were assessed while on medication, which can mask subtle motor changes. There was no washout period to distinguish symptomatic effects from disease progression. Brain imaging lacks sensitivity to detect small changes in neurodegeneration over one year. Serious adverse events occurred in 8.3 percent of the nicotinamide riboside group and 14.1 percent of the placebo group—a difference that was not statistically significant.
The clinical relevance of these findings extends beyond the research setting. Nicotinamide riboside is sold over the counter as a dietary supplement and is widely used by people seeking to optimize health and slow aging. The trial provides no evidence that it helps Parkinson's patients and suggests it may cause modest harm. Researchers continue to investigate NAD supplementation in other contexts, but for early Parkinson's disease at the dose and duration tested, the case for nicotinamide riboside has closed.
Notable Quotes
These findings do not support nicotinamide riboside as a disease-modifying treatment for Parkinson's disease.— Trial authors, published in JAMA
The results did not support its use as a symptomatic treatment for Parkinson disease at the dose and duration tested.— Trial authors
Want the full story?
Read the original at News-Medical ↗
Health & Medicine